Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for paroxysmal atrial fibrillation in patients with type 2 diabetes mellitus
ChiCTR1900026430Phase 4Not yet recruiting
- Sponsor
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine
- Start
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of exenatide in Atrial fibrillation (AFib) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Jiangsu Province Hospital on Integration of Chinese and Western Medicine. Primary endpoints: Left ventricular ejection fraction, Frequency of atrial fibrillation and 7 more. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
exenatide
03
Conditions
Atrial fibrillation (AFib)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900026430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026430.